Henk C. Hoogsteden
Erasmus University Medical Center
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Henk C. Hoogsteden.
Nature Medicine | 2007
Marco Idzko; Hamida Hammad; Menno van Nimwegen; Mirjam Kool; Monique Willart; Femke Muskens; Henk C. Hoogsteden; Werner Luttmann; Davide Ferrari; Francesco Di Virgilio; J. Christian Virchow; Bart N. Lambrecht
Extracellular ATP serves as a danger signal to alert the immune system of tissue damage by acting on P2X or P2Y receptors. Here we show that allergen challenge causes acute accumulation of ATP in the airways of asthmatic subjects and mice with experimentally induced asthma. All the cardinal features of asthma, including eosinophilic airway inflammation, Th2 cytokine production and bronchial hyper-reactivity, were abrogated when lung ATP levels were locally neutralized using apyrase or when mice were treated with broad-spectrum P2-receptor antagonists. In addition to these effects of ATP in established inflammation, Th2 sensitization to inhaled antigen was enhanced by endogenous or exogenous ATP. The adjuvant effects of ATP were due to the recruitment and activation of lung myeloid dendritic cells that induced Th2 responses in the mediastinal nodes. Together these data show that purinergic signaling has a key role in allergen-driven lung inflammation that is likely to be amenable to therapeutic intervention.
PLOS ONE | 2010
Jun Hou; Joachim Aerts; Bianca den Hamer; Wilfred van IJcken; Michael A. den Bakker; Peter Riegman; Cor van der Leest; Peter J. van der Spek; John A. Foekens; Henk C. Hoogsteden; Frank Grosveld; Sjaak Philipsen
Background Current clinical therapy of non-small cell lung cancer depends on histo-pathological classification. This approach poorly predicts clinical outcome for individual patients. Gene expression profiling holds promise to improve clinical stratification, thus paving the way for individualized therapy. Methodology and Principal Findings A genome-wide gene expression analysis was performed on a cohort of 91 patients. We used 91 tumor- and 65 adjacent normal lung tissue samples. We defined sets of predictor genes (probe sets) with the expression profiles. The power of predictor genes was evaluated using an independent cohort of 96 non-small cell lung cancer- and 6 normal lung samples. We identified a tumor signature of 5 genes that aggregates the 156 tumor and normal samples into the expected groups. We also identified a histology signature of 75 genes, which classifies the samples in the major histological subtypes of non-small cell lung cancer. Correlation analysis identified 17 genes which showed the best association with post-surgery survival time. This signature was used for stratification of all patients in two risk groups. Kaplan-Meier survival curves show that the two groups display a significant difference in post-surgery survival time (pu200a=u200a5.6E-6). The performance of the signatures was validated using a patient cohort of similar size (Duke University, nu200a=u200a96). Compared to previously published prognostic signatures for NSCLC, the 17 gene signature performed well on these two cohorts. Conclusions The gene signatures identified are promising tools for histo-pathological classification of non-small cell lung cancer, and may improve the prediction of clinical outcome.
Journal of Immunology | 2003
Leonie S. van Rijt; Nanda Vos; Daniëlle Hijdra; Victor C. de Vries; Henk C. Hoogsteden; Bart N. Lambrecht
Asthma is characterized by infiltration of the airway wall with eosinophils. Although eosinophils are considered to be effector cells, recent studies have reported their ability to activate primed Th2 cells. In this study, we investigated whether eosinophils are capable of presenting Ag to unprimed T cells in draining lymph nodes (DLN) of the lung and compared this capacity with professional dendritic cells (DC). During development of eosinophilic airway inflammation in OVA-sensitized and challenged mice, CCR3+ eosinophils accumulated in the DLN. To study their function, eosinophils were isolated from the bronchoalveolar lavage fluid of mice by sorting on CCR3+B220−CD3−CD11cdim low autofluorescent cells, avoiding contamination with other APCs, and were intratracheally injected into mice that previously received CFSE-labeled OVA TCR-transgenic T cells. Eosinophils did not induce divisions of T cells in the DLN, whereas DC induced on average 3.7 divisions in 45.7% of T cells. To circumvent the need for Ag processing or migration in vivo, eosinophils were pulsed with OVA peptide and were still not able to induce T cell priming in vitro, whereas DC induced vigorous proliferation. This lack of Ag-presenting ability was explained by the very weak expression of MHC class II on fresh eosinophils, despite expression of the costimulatory molecules CD80 and ICAM-1. This investigation does not support any role for airway eosinophils as APCs to naive T cells, despite their migration to the DLN at times of allergen exposure. DC are clearly superior in activating T cells in the DLN of the lung.
Journal of Immunology | 2014
Alex Kleinjan; Roel G. J. Klein Wolterink; Yelvi Levani; Marjolein J. W. de Bruijn; Henk C. Hoogsteden; Menno van Nimwegen; Rudi W. Hendriks
Airway inflammation in allergic asthma reflects a threshold response of the innate immune system, including group 2 innate lymphoid cells (ILC2), followed by an adaptive Th2 cell–mediated response. Transcription factor Gata3 is essential for differentiation of both Th2 cells and ILC2. We investigated the effects of enforced Gata3 expression in T cells and ILC2 on the susceptibility of mice to allergic airway inflammation (AAI). We used CD2-Gata3 transgenic (Tg) mice with enforced Gata3 expression driven by the CD2 promoter, which is active both in T cells and during ILC2 development. CD2-Gata3 Tg mice and wild-type (WT) littermates were analyzed in mild models of AAI without adjuvants. Whereas OVA allergen exposure did not induce inflammation in WT controls, CD2-Gata3 Tg mice showed clear AAI and enhanced levels of IL-5 and IL-13 in bronchoalveolar lavage. Likewise, in house dust mite–driven asthma, CD2-Gata3 Tg mice were significantly more susceptible to AAI than WT littermates, whereby both ILC2 and Th2 cells were important cellular sources of IL-5 and IL-13 in bronchoalveolar lavage and lung tissue. Compared with WT littermates, CD2-Gata3 Tg mice contained increased numbers of ILC2, which expressed high levels of IL-33R and contributed significantly to early production of IL-4, IL-5, and IL-13. CD2-Gata3 Tg mice also had a unique population of IL-33–responsive non-B/non-T lymphoid cells expressing IFN-γ. Enforced Gata3 expression is therefore sufficient to enhance Th2 and ILC2 activity, and leads to increased susceptibility to AAI after mild exposure to inhaled harmless Ags that otherwise induce Ag tolerance.
Journal of Thoracic Oncology | 2012
Jun Hou; Margaretha Lambers; Bianca den Hamer; Michael A. den Bakker; Henk C. Hoogsteden; Frank Grosveld; Joost Hegmans; Joachim Aerts; Sjaak Philipsen
Introduction: A challenge of cancer therapy is to optimize therapeutical options to individual patients. Cancers with similar histology may show dramatically different responses to therapy, indicating that a refined approach needs to be developed to classify tumors by intrinsic characteristics that may predict response to chemotherapy. Global expression profile-based classification has the potential to identify such tumor-intrinsic subclasses. Pemetrexed effectiveness has been related to the expression of its target thymidylate synthase. The relatively frequent resistance of squamous cell carcinoma to Pemetrexed is correlated with high levels of thymidylate synthase expression. Methods: A global expression profile-based molecular classification of non-small cell lung cancer (NSCLC) was performed. Gene expression was used to predict Pemetrexed responsiveness. The distinct molecular attributes of NSCLCs predicted likely to be resistant to Pemetrexed were bioinformatically characterized. We tested if routine immunohistochemical markers can be used to distinguish putative Pemetrexed responders, predicted by gene signatures, from nonresponders. Results: Ninety NSCLCs were divided into six subclasses by gene expression signatures. The relevance of this novel phenotyping was linked to other tumor characteristics. Two of the subclasses correlated to putative Pemetrexed resistance. In addition, the identified signature genes characterizing putative Pemetrexed responsiveness predicted therapeutic benefit in a subset of squamous cell carcinoma. Conclusions: Gene expression signatures can be used to identify NSCLC subgroups and have potential to predict resistance to Pemetrexed therapy. We suggest that a combination of classical pathological markers can be used to identify molecular tumor subclasses associated with predicted Pemetrexed response.
World Journal of Respirology | 2015
Marieke de Heer; Robin Cornelissen; Henk C. Hoogsteden; Leon M. van den Toorn
Management of recurrent malignant pleural effusions with a tunneled indwelling pleural catheter
The Journal of Allergy and Clinical Immunology | 2001
Gert-Jan Braunstahl; Shelley E. Overbeek; Alex Kleinjan; Jan-Bas Prins; Henk C. Hoogsteden; Wytske Fokkens
American Journal of Respiratory and Critical Care Medicine | 2000
Gert-Jan Braunstahl; Alex Kleinjan; Shelley E. Overbeek; Jan-Bas Prins; Henk C. Hoogsteden; Wytske Fokkens
Journal of Immunological Methods | 2004
Leonie S. van Rijt; Harmjan Kuipers; Nanda Vos; Daniëlle Hijdra; Henk C. Hoogsteden; Bart N. Lambrecht
The Journal of Allergy and Clinical Immunology | 2004
Leonie S. van Rijt; Nanda Vos; Monique Willart; Alex Kleinjan; Anthony J Coyle; Henk C. Hoogsteden; Bart N. Lambrecht